Skip to main content
. 2018 Nov 30;19:424. doi: 10.1186/s12891-018-2338-6

Table 2.

Comparison of SSE incidence between groups

Variable Denosumab (n = 120) ZA(n = 122) P - value
Total incidence of SSEs 10/120 21/122 0.04*a
SSE incidence
within 2 years 3/120 4/122 0.21a
after 2 years 7/120 17/122 0.04*a

* Statistically significant values. aAnalysed using the Chi-square test. ZA: zoledronic acid; SSEs: symptomatic skeletal events